GSK, Roche and Novo back $86 million immuno-oncology startup
August 17, 2016Research and Development CD47, Cancer, GSK, Novo, Roche, Tioma, oncology
Brisbane-based venture-stage biopharmaceutical company Tioma Therapeutics has announced it has raised $86 million in Series A venture financing for its …
Amgen, Sanofi cholesterol medicines “not cost-effective”, need to drop price by two-thirds
August 17, 2016Research and Development, Sales and Marketing Amgen, QALY, Regeneron, Repatha, Sanofi, cost effective, cost-effective, praluent
A new study published in JAMA has suggested that Amgen, Sanofi and Regeneron would have to reduce their prices for …
ViiV Healthcare launches Phase III trial for combo HIV treatment
August 16, 2016Research and Development Dolutegravir, HIV, Tivicay, ViiV Healthcare, epivir, lamivudine, phase III
The Pfizer/GSK spin off ViiV Healthcare has announced the beginning of a Phase III evaluating Tivicay (dolutegravir) and Epivir (lamivudine) …
MSD to cut 148 jobs at Pennsylvania plant
August 16, 2016Manufacturing and Production, Research and Development MSD, job cuts, zontivity
MSD is due to cut 148 jobs at its North Wales, Pennsylvania campus effective September 12, according to the company’s …
Ashfield launches Global Impact On Society Initiative
August 16, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Ashfield, part of UDG Healthcare plc (LON: UDG), a global leader in providing outsourced healthcare services to pharmaceutical, device and …
13 deaths in Aurinia’s lupus drug trial despite hitting Phase II target
August 16, 2016Manufacturing and Production, Research and Development Aurinia, Phase II, biotech, patient deaths, voclosporin
Canadian biotech Aurinia Pharmaceuticals has announced the topline Phase IIb trial results of its lupus nephritis (LN) treatment voclosporin, which …
Vertex stumbles in Phase III cystic fibrosis trials
August 16, 2016Manufacturing and Production, Research and Development Vertex, cystic fibrosis, phase III
Vertex Pharmaceuticals has provided an update on its ongoing Phase III trials investigating VX-661 in combination with Kalydeco (ivacaftor) in …
US court rules in favour of UCB in patent dispute, shares jump
August 16, 2016Manufacturing and Production, Research and Development, Sales and Marketing UCB, lacosamide, patent, vimpat
UCB has received a major boost after a Delaware district court confirmed the validity of the company’s patents on one …
FDA finds drug class at centre of French trial tragedy do not pose similar safety risks
August 15, 2016Manufacturing and Production, Research and Development Bial, Biotrial, FDA, faah, rennes
The US Food and Drug Administration (FDA) has issued a statement following the results of their investigation into the recent …
UK Government commits to funding EU research projects after Brexit
August 15, 2016Manufacturing and Production, Research and Development brexit, research
Chancellor Phillip Hammond has outlined a government commitment to guarantee EU funding for British research projects made before Britain leaves …
Top ten stories in the pharmaceutical industry this week
August 15, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biggest stories, pharma, pharmafile, stories of the week, top 10
It’s Monday and we’re just getting back to it after a busy week in pharma. Unfortunately, it was mostly bad …
Acute coronary syndrome market to grow to over $12 billion by 2022
August 15, 2016Research and Development, Sales and Marketing GlobalData, acute coronary syndrome
The acute coronary syndrome (ACS) market is forecast to rise from $7.8 billion in 2015 to $12.1 billion by 2022 …
Endo to withdraw FDA application for abuse-deterrent labelling on opioid drug
August 15, 2016Sales and Marketing Endo, Endo International, abuse deterrent, opioid
Endo International has announced that, following discussions with the US Food and Drug Administration (FDA), it has decided to withdraw …
Novartis invests €100 million to expand French manufacturing plant
August 15, 2016Manufacturing and Production, Sales and Marketing Novartis, manufacturing
Novartis has sealed the deal with construction firm Jacobs Engineering group to expand production operations at its France Center of …
Sanofi launches dengue immunisation program in Brazil
August 15, 2016Research and Development, Sales and Marketing Brazil, Sanofi, Sanofi Pasteur, Vaccine, dengue, immunisation, vaccines
Sanofi has announced that it has initiated the first dengue immunisation public program in the Americas, with 500,000 individuals set …
Study shows promise for Venclexta in acute myelogenous leukaemia
August 12, 2016Research and Development, Sales and Marketing AbbVie, Genentech, Roche, Venclexta, venetoclax
A study published in Cancer Discovery, the journal of the American Association for Cancer Research, suggests that Vencletxa (venetoclax) is …
Promising results for new type 2 diabetes management procedure
August 12, 2016Research and Development, Sales and Marketing Fractyl, Revita, diabetes, type 2 diabetes
Fractyl Laboratories has revealed data from its first-in-human study of Revita duodenal mucosal resurfacing (Revita DMR), a new 60-minute, non-surgical …
Ashfield publishes a guide to Patient Support Programmes: Ten steps to success
August 12, 2016Medical Communications, Research and Development, Sales and Marketing
The priorities of Pharma and healthcare organisations are better aligned as a result of the industry’s increased efforts to put …
Number of babies born with opioid dependence has tripled in US, says CDC report
August 12, 2016Medical Communications, Research and Development CDC, addicted, babies, opioid dependence, opioids
A new report from the Centers for Disease Control and Prevention (CDC) has highlighted a sharp increase in the number …
Allergan set to acquire eye-care biotech ForSight VISION5
August 12, 2016Medical Communications, Sales and Marketing Allergan, ForSight VISION5, acquisition, biotech, eye care
Allergan has announced its acquisition of privately-held, clinical-stage eye-care biotech ForSight VISION5 for a $95 million upfront payment and a …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
